No approved hantavirus vaccine exists as of mid-2026, with all candidates still in preclinical stages or early Phase 1 testing that has not advanced to later efficacy trials. Recent outbreaks, including a notable 2026 Andes virus incident on a cruise ship, have heightened research urgency and prompted renewed funding discussions, yet experts from institutions like the University of Bath and the U.S. Army Medical Research Institute of Infectious Diseases note that typical timelines for completing Phase 2 and 3 trials, regulatory review, and manufacturing scale-up extend well beyond the year’s end without an Operation Warp Speed-scale acceleration. Model predictions and historical precedent for rodent-borne viral vaccines underscore the significant barriers posed by sporadic case patterns and limited commercial incentives, aligning with trader consensus on the low likelihood of resolution by December 2026.